Skip to content

Pexidartinib

Kinase Inhibitor — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Also known as: CML-261, pexidartinib hydrochloride, PLX3397, turalio

OnpFDA approvedOrphan designationATC L01EX15

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Pexidartinib is an onp drug in the Kinase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2019. Its mechanism of action is classified as Colony Stimulating Factor Receptor Type 1 (CSF-1R) Inhibitors, Cytochrome P450 2B6 Inhibitors and Cytochrome P450 3A Inducers. DrugCentral lists 15 molecular targets, including PRKCQ, PDGFRA and CSF1R. Recorded indications include Tenosynovial giant cell tumor.

  • Approval status: onp (first approved 2019 by the FDA).
  • Drug class: Kinase Inhibitor.
  • Mechanism of action: Colony Stimulating Factor Receptor Type 1 (CSF-1R) Inhibitors; Cytochrome P450 2B6 Inhibitors; Cytochrome P450 3A Inducers.
  • Molecular targets: PRKCQ, PDGFRA, CSF1R and Csf1r (15 listed in DrugCentral).
  • Indications: Tenosynovial giant cell tumor.
  • ATC code: L01EX15 (Other protein kinase inhibitors).
  • Molecular formula: C20H15ClF3N5; molecular weight 417.82 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • Tenosynovial giant cell tumor

Mechanism & targets

Mechanism of action (MoA)Colony Stimulating Factor Receptor Type 1 (CSF-1R) Inhibitors; Cytochrome P450 2B6 Inhibitors; Cytochrome P450 3A Inducers; Kinase Inhibitors; Tyrosine Kinase Inhibitors; UGT1A1 Inhibitors
Established pharmacologic classKinase Inhibitor

Molecular targets (15)

TargetGeneActionActivity
Protein kinase C theta typePRKCQunknownKd 8.22
Platelet-derived growth factor receptor alphaPDGFRAunknownIC50 8.02
Macrophage colony-stimulating factor 1 receptorCSF1RinhibitorIC50 7.88
Macrophage colony-stimulating factor 1 receptorCsf1runknownIC50 7.85
Mast/stem cell growth factor receptor KitKITinhibitorIC50 7.56
Platelet-derived growth factor receptor betaPDGFRBunknownIC50 7.44
Cyclin-dependent kinase 19CDK19inhibitorIC50 6.85
Receptor-type tyrosine-protein kinase FLT3FLT3inhibitorIC50 6.79
Vascular endothelial growth factor receptor 2KDRinhibitorIC50 6.36
Aurora kinase BAURKBunknownIC50 6.19
Tyrosine-protein kinase LckLCKinhibitorIC50 6.07
Vascular endothelial growth factor receptor 1FLT1inhibitorIC50 6.06
NT-3 growth factor receptorNTRK3inhibitorIC50 6.05
Uncharacterized protein FLJ45252—unknownKd 5.84
AP2-associated protein kinase 1AAK1unknownKd 4.86

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
2019-08-02FDA—DAIICHI SANKYO INCYes

ATC classification

ATC codeTherapeutic hierarchy
L01EX15ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › PROTEIN KINASE INHIBITORS › Other protein kinase inhibitors

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Hair colour changes837.2
Product dose omission issue243.6
Aspartate aminotransferase increased161.0
Alanine aminotransferase increased133.3
Gamma-glutamyltransferase increased129.3
Blood alkaline phosphatase increased121.8
Fatigue103.8
Periorbital swelling103.1
No adverse event88.6
Therapy cessation86.5
Pruritus61.1
Blood bilirubin increased60.1

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Pexidartinib is on its molecule page.

Molecular formulaC20H15ClF3N5
Molecular weight417.82 g/mol
CAS number1029044-16-3
InChIKeyJGWRKYUXBBNENE-UHFFFAOYSA-N
PubChem CID25151352
FC(F)(F)C1=CC=C(CNC2=NC=C(CC3=CNC4=NC=C(Cl)C=C34)C=C2)C=N1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Pexidartinib used for?

DrugCentral lists the following indications for Pexidartinib: Tenosynovial giant cell tumor.

How does Pexidartinib work?

Pexidartinib is classified as Colony Stimulating Factor Receptor Type 1 (CSF-1R) Inhibitors, Cytochrome P450 2B6 Inhibitors and Cytochrome P450 3A Inducers; its molecular targets in DrugCentral include PRKCQ, PDGFRA, CSF1R (inhibitor) and Csf1r.

When was Pexidartinib first approved?

Pexidartinib was first approved by the FDA in 2019.

What drug class does Pexidartinib belong to?

Pexidartinib is in the Kinase Inhibitor class.

What is the chemical formula of Pexidartinib?

Pexidartinib has the molecular formula C20H15ClF3N5 and a molecular weight of 417.82 g/mol.

Browse: all drugs starting with P · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusONP
First approval2019-08-02
AgencyFDA
Targets15
Indications1
FormulaC20H15ClF3N5
DrugCentral ID5343
Interactive profile